LB Pharmaceuticals Inc
LBRX
$29.66
-$1.75-5.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.17M | -25.42M | -19.02M | -29.65M | -52.25M |
| Total Depreciation and Amortization | 325.50K | 322.50K | 317.50K | 241.50K | 167.00K |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 3.22M | 3.22M |
| Total Other Non-Cash Items | 5.60M | 3.04M | 2.40M | 1.12M | 3.07M |
| Change in Net Operating Assets | -18.39M | -14.41M | -7.73M | -17.63M | -5.81M |
| Cash from Operations | -51.63M | -36.47M | -24.03M | -42.70M | -51.61M |
| Capital Expenditure | -78.00K | -67.00K | -265.00K | -708.00K | -743.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.34M | -37.33M | -23.56M | 50.59M | 55.02M |
| Cash from Investing | -42.41M | -37.40M | -23.82M | 49.89M | 54.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 428.03M | 328.00M | 328.00M | 20.00K | 23.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.63M | -25.44M | -24.27M | 0.00 | 0.00 |
| Cash from Financing | 396.39M | 302.56M | 303.73M | 20.00K | 23.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 302.35M | 228.69M | 255.88M | 7.21M | 2.69M |